HVIVO PLC Secures $11.5 Million in Funding for Cutting-Edge Infectious Disease Research

We are thrilled to announce that hVIVO plc (ticker: HVO) has successfully raised £11.5 million to further bolster our leading position in the specialized contract research organization (CRO) market. As the world leader in testing infectious and respiratory disease vaccines and therapeutics through human challenge clinical trials, this new funding will enable us to expand our innovative services and develop additional human challenge models to meet the growing demand from our extensive client base, which includes four of the top ten global biopharma companies. With this investment, hVIVO plans to enhance its state-of-the-art facilities in Canary Wharf, London's premier commercial human challenge trial unit, further developing our capabilities in virology and immunology research. This funding will not only help in advancing our unique portfolio of 11 human challenge models but also support our comprehensive drug development and clinical consultancy services under our Venn Life Sciences brand. Additionally, the investment will enhance our labs’ offerings through hLAB, where we conduct vital virology, immunology biomarker, and molecular testing. At hVIVO, our mission is to accelerate the development of lifesaving therapies and vaccines, and we are committed to leveraging our world-class challenge agent manufacturing capabilities and unparalleled patient recruitment services through our FluCamp facilities. This funding marks a significant milestone in our ongoing commitment to pioneering advancements in clinical research, ultimately leading to better health outcomes for individuals around the globe. We look forward to what lies ahead as we embark on the next stages of our growth and innovation journey.